ArticleCancer pathogenesis and therapy2025

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.